Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of June 11, 2026 And Rigel Has Made The Upfront Payment Of $70.0M To Be Distributed Evenly Between Arvinas And Pfizer, Consistent With The Terms Of The Agreement

뉴스 본문을 불러오고 있어요.

Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of June 11, 2026 And Rigel Has Made The Upfront Payment Of $70.0M To Be Distributed Evenly Between Arvinas And Pfizer, Consistent With The Terms Of The Agreement | 웨이프 WAPE

Rigel Pharmaceuticals Closes Its Licensing Agreement for VEPPANU; The Agreement Is Effective As Of June 11, 2026 And Rigel Has Made The Upfront Payment Of $70.0M To Be Distributed Evenly Between Arvinas And Pfizer, Consistent With The Terms Of The Agreement

기사 요약

관련 종목

댓글 —